Topic Listing for NeurogesX

Acetaminophen Prodrug Candidates-preclinical Program Acquisition Bonus Plan
Acquisition Bonus Plan Amended 2008 Additional Studies Phn
Adopted 2008 Adopted 2009
Adoption New Accounting Standard Adoption Sfas 123r
Alterations Additions Amendment Lease
Anthony Ditonno Anthony Ditonno Continuing Remarks
Anthony Ditonno Remarks Anthony Ditonno Wrap-up Statement
Anti-takeover Provisions Charter Documents Delaware Law Make Acquisition Approvals Outside United States European Union
Approved Peripheral Neuropathic Pain Non-diabetic Adults Astellas Pharma Europe Ltd
Available Information Background
Base Compensation Basis Presentation
Batch Accompanying Documentation Batch Prices
Benchmarking Elements Compensation Beneficial Ownership Reporting Compliance
Board Meetings Committees Bonus Compensation
Bridgepointe Parkway Suite 200 Building 2215 Bridgepointe Parkway San Mateo
Call Scheduled 2009 9am Cannot Predict Whether Regulatory Agencies Determine Data Clinical
Cannot Predict Whether Regulatory Agencies Determine Data Ngx-4010 Capsaicin Dermal Patch Since 2009
Capsaicin-induced Effects Peripheral Neuropathic Pain Carol Ruth Safe Harbor
Cash Equivalents Short Term Investments Changes Financial Condition
Chmp Commitment Clinical Development Update
Clinical Trial Phases Clinical Trial Results
Clinical Trials Clinical Trials Fail Demonstrate Adequately Safety Efficacy Product
Code Ethics Collaboration Agreement Astellas
Collaboration Arrangements Commencement Agreement
Commercial Success Ngx-4010 Depends Part Rights Certain Patents Commercial Success Qutenza Depends Part Rights Certain Patents
Commercial Supply License Agreement Commercialization
Commitments Contingencies Common Stock
Comparison 2006 2005 Comparison 2007 2006
Comparison 2008 2007 Comparison 2009 2008
Comparison Historical Cumulative Total Return Among Neurogesx Inc Compensation Committee Interlocks Insider Participation
Compensation Philosophy Objectives Competition
Comprehensive Loss Concentrations Credit Risk Financial Instruments
Conference Call Details Conference Call Scheduled Friday 9am
Conference Call Webcast Information Confidentiality
Consent Independent Registered Public Accounting Firm Continue Incur Increased Costs Demands Management Result Complying
Contractual Obligations Cooperation Terms
Coordination Corporate Highlights
Critical Accounting Policies Significant Judgments Estimates Cubes-standard Kimball Cetra Footprint Furniture Contain
Data Exclusivity Deadline Receipt Stockholder Proposals
Deferred Offering Costs Deferred Stock Based Compensation
Deferred Stock-based Compensation Definitions
Delays Commencement Completion Clinical Testing Result Increased Costs Departure Directors Certain Officers Election Appointment Compensatory
Departure Directors Certain Officers Election Appointment Compensatory Arrangements Depend Key Personnel Not Able Retain Them Business
Development Development Plan
Development Stage Development Update
Director Compensation Directors Executive Officers
Discussion Analysis Read Conjunction Financial Statements Accompanying Notes Dispute Resolution
Distribution Marketing License Agreement Documentation Provided Ngx
Documents Incorporated Reference Effects Termination
Elizabeth Scott Safe Harbor Employees
Employment Agreements End 2007 Financial Results
Enter Agreement Depend Partners Assist Commercializing Lead Product Entry Material Definitive Agreement
Equity Awards Estimates
Estimation Fair Value Warrants Purchase Redeemable Convertible Preferred European Union
Europeregistrycom Even Clinical Trials Ngx-4010 Treatment Phn Hiv-dsp Successful
Even Product Candidates Receive Regulatory Approval They Subject Events Credit Markets Continue Impact Investment Returns
Exact Name Registrant Specified Charter Except Share Per Data
Exchange Act 1934 Amendment Executive Compensation
Executive Employment Agreement Exhibits
Existing Treatments Limitations Expect Stock Price Fluctuate Significantly Not Able Resell
Explanatory Face Potential Product Liability Exposure Successful Claims Brought
Face Substantial Competition Result Others Discovering Developing Commercializing Facilities
Fail Comply Obligations Agreements License Development Commercialization Rights Fair Value Measurements
Fair Value Warrants Issued Fast Track Designation Development Ngx-4010 Treatment Painful Hiv-associated
Fast Track Designation Development Qutenza Treatment Painful Hiv-associated Fast Track Designation Priority Review
Financial Results Financial Statements Exhibits
Follow-up Measures Foreign Currency Exchange Rate Risk
Form 10-k Form 10-q
Form Letter Credit Form Organization
Former Address Former Name Address Changed Since Last Report
Formosa Laboratories Inc Future Sales Shares Existing Stockholders Cause Stock Price
General Grant Exercise Option Landlord Grants Tenant Lease Building
Grants Plan-based Awards Guarantees Indemnifications
Hatch-waxman Act Highlights
Immediate Release Includes Licensing Option Development Funding Ngx-1998
Income Taxes Incur Increased Costs Demands Management Result Complying Laws
Incur Substantial Costs Result Litigation Other Proceedings Relating Incurred Operating Losses Each Since Inception Expect Continue
Indebtedness Management Indemnification
Indemnification Directors Officers Independence Directors
Independent Registered Public Accounting Firm Ending 2008 Independent Registered Public Accounting Firm Ending 2009
Index Index Consolidated Financial Statements
Initial Payments Milestones Initial Public Offering
Initial Public Offering Proceeds Initial Subtenant Alterations
Instrument Adherence Intellectual Property
Interest Expense Interest Rate Market Risk
Internet Availability Proxy Materials Inventory
Investor Name Address Jeffrey Tobias
Jeffrey Tobias Remarks Jsc Commercialization Plan Existing Product
Keith Bley Phd Key Metrics
Landlords Liability Lead Product Candidate Ngx-4010
Legal Opinion Liability
License Agreement Licenses
Limited Experience Regulatory Affairs Liquid Formulation Ngx-1998
Liquidity Capital Resources Lts Agreement
Lts Lohman Therapie-systeme Lts Lohmann Therapie-systeme
Management Auditors Identified Material Weaknesses Internal Controls Part Manufacturing
Manufacturing Capabilities Depend Other Parties Operations Manufacturers Fail Manufacturing Process Development
Manufacturing Supply Agreement Marketing Application Submitted Schedule
Marketing Approval Including Packaging Information Specifications Also Include Marketing Authorization
Marketing Authorizations Regulatory Material Weaknesses Identified Prior
Maximum Capacity Maximum Order Quantity
Michael Markels Miscellaneous
Name Person Filing Proxy Statement Other Registrant Nature Operation Basis Preparation
Nature Operations Net Loss Per Share
Networksolutionscom Neurogesx Appoints New Director Board
Neurogesx Inc Neurogesx Ngx-4010 Maa Filed Accepted Review Emea Treatment
Neurogesx Receives Fda Approval Qutenza Capsaicin Patch Treatment Neuropathic Pain
Neuropathic Pain Conditions Never Paid Dividends Capital Stock Not Anticipate Paying
New Drug Application Ngx-1998-liquid High Concentration Topical Capsaicin
Ngx-4010 Ngx-4010-initial Target Indications
Ngx-6052 Opioid Analgesic Prodrug Preclinical Program Nominees
Not Able Maintain Orphan Drug Exclusivity Qutenza Phn Not Able Obtain Hatch-waxman Act Data Exclusivity Equivalent
Not Able Obtain Hatch-waxman Act Marketing Exclusivity Equivalent Not Able Obtain Maintain Orphan Drug Exclusivity Ngx-4010
Not Able Obtain Maintain Orphan Drug Exclusivity Qutenza Not Raise Additional Capital Forced Delay Reduce Eliminate
Not Raise Additional Capital Forced Further Delay Reduce Not Successful Obtaining European Regulatory Approval Ngx-4010
Not Successful Obtaining European Regulatory Approval Qutenza Not Yet Adopted
Notes Receivable Stockholders Off-balance Sheet Arrangements
Only Prescription Strength Capsaicin Product Provide Reduced Pain Operating Leases
Operator Opioid Analgesic Prodrugs-preclinical Program
Options Exercised Stock Vested Orphan Drug Designation
Other Benefits Other Events
Other Matters Other Regulatory Requirements
Overview Overview Compensation Program
Ownership Common Stock Continues Highly Concentrated Prevent Other Ownership Licenses
Painful Diabetic Neuropathy Painful Hiv-distal Sensory Polyneuropathy
Part Part Other Information
Patents Proprietary Rights Patient Study Evaluate Fda-approved Topical Anesthetic Pretreatment
Payment Payments
Payments Books Records Persons Contact
Phn Hiv-dsp Physicians Not Adequately Reimbursed Time Services Administering Ngx-4010
Physicians Not Adequately Reimbursed Time Services Administering Qutenza Policies Procedures Related Party Transactions
Postherpetic Neuralgia Postherpetic Neuralgia Phn
Potential Market Exclusivity Phn Pending Product Approval Potential Payments Termination Change Control
Power Attorney Preclinical Studies
Preferred Stock Warrant Liability Preferred Stock Warrant Liability Redeemable Convertible
Preferred Stock Warrants Premises
Prepaid Collaboration Supplies Present
Press Release Principal Accountant Fees Services
Principles Consolidation Private Placement
Pro Forma Information Product Candidates Never Achieve Market Acceptance Even Obtain
Product Candidates Never Achieve Market Acceptance Even They Product Description
Product Development Programs Product Trademark Alternative
Product Warranties Products Expected Face Substantial Competition Result Others Discovering
Property Equipment Purchase Order
Purchase Order Form Purchase Order Number Appear Invoices Correspondence
Purchasers Certificate Subsequent Sale Pursuant 302 Sarbanes-oxley Act 2002
Q09 Corporate Highlights Quality
Quality Agreement Quality Regulatory Issues
Quorum Abstentions Broker Non-votes Qutenza
Qutenza Since 2009 Raising Additional Funds Issuing Securities Through Licensing Arrangements
Receives Nasdaq Notice Regarding Audit Committee Compliance Recent Developments
Recent Events Credit Markets Continue Impact Investment Returns Recent Events Credit Markets Increased Risk Cash Equivalents
Recently Issued Accounting Standards Recitals
Record Date Share Ownership Regains Nasdaq Compliance
Registrants Telephone Number Including Area Code Registrants Telephone Number Including Area Code 650 358-3300
Registrants Telephone Number Including Area Code 650 508-2116 Regulation Disclosure
Regulatory Commercialization Plans Ngx-4010 Regulatory Matters
Regulatory Reviews Now Underway Europe Rely Parties Conduct Clinical Trials Not Perform Contractually
Rely Parties Conduct Non-clinical Clinical Trials Not Perform Rely Parties Conduct Non-clinical Studies Clinical Trials Not
Remainder Page Intentionally Left Blank Remediation Prior Material Weaknesses
Rental Adjustment Report Audit Committee Board Directors
Report Compensation Committee Board Directors Report Independent Registered Public Accounting Firm
Representations Warranties Representations Warranties Disclaimer Limitation Liability
Require Substantial Additional Funding Unable Raise Capital Needed Research Development
Restated Executive Employment Agreement Restricted Stock Purchases
Results Fda-requested Qutenza Study Results Operations
Results Operations Financial Condition Revenue Recognition
Reverse Stock Split Revocability Proxies
Risk Factors Risks Related Business
Risks Related Finances Capital Requirements Role Executive Officers Compensation Decisions
Rules Regulations Safe Harbor Statement
Sales Marketing Distribution Sarbanes-oxley Act 2002
Schedule Purchasers Schedules Investor Conference Call 500 Est
Securities Exchange Securities Exchange Act 1934
Securities Registered Pursuant Act Security Deposit
Services Severance Change Control Payments
Shares Reserved Future Issuances Shares Warrants Issued Insiders
Signatures Signatures Next Page
Solicitation Proxies Solution
Stability Testing Program Standard Private Offices Kimball Cetra Footprint Furniture Contain
Stephen Stephen Ghiglieri
Stock Incentive Plan Stock Incentive Plan 2007
Stock Options Granted Nonemployees Stock Plan
Stock-based Compensation Stockholders Equity
Strategy Subject Damages Resulting Claims Employees Wrongfully Used Disclosed
Success Depend Part Successful Efforts Collaboration Partner European Success Depends Ability Obtain Regulatory Approval Lead Product
Success Depends Substantially Ability Obtain Regulatory Approval Lead Sued Infringing Intellectual Property Rights Other Parties Such
Supply Supply Agreement
Supply Existing Product Susan Rinne
Term Termination Territory
Text Initial Patch Backing Third-party Reimbursement Pricing Controls
Tony Ditonno Trademarks
Transfer Marketing Authorisation Transfer Price
Trg Trial Meets Primary Secondary Endpoints
Unable Establish Sales Marketing Distribution Infrastructure Enter Collaborations Unable Maintain Enforce Proprietary Rights Not Able Compete
United States University California
Upcoming 2009 Milestones Vote Required
Voting Vr1-ligands
Warrant Exercises Warrants Purchase Common Stock
Witnesseth Wttnesseth
Year-end 2008 Financial Results 
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki